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Abstract:
Many autoimmune diseases, including multiple sclerosis (MS), rheumatoid arthritis (RA), and
celiac disease (CD), arise from improper immune system recognition of self or benign peptides as
threats. No autoimmune disease currently has a cure. Many treatments suppress the entire immune
system to decrease symptom severity. The core molecular interaction underlying these diseases
involves specific alleles of the human leukocyte antigen (HLA) receptor hosting the
immunodominant peptides associated with the disease (i.e. myelin basic protein, Type II collagen,
or α-gliadin) in their binding groove. Once bound, circulating T-cells can recognize the HLAantigen complex and initiate the complex cascade that forms an adaptive immune response. This
initial HLA-antigen interaction is a promising target for therapeutic intervention. Two general
strategies have been pursued: altered peptide ligands (APLs) that attempt to recruit a different class
of T-cell to induce an anti-inflammatory response to balance the pro-inflammatory response
associated with the antigen; and HLA blockers (HLABs), peptides that, due to a much higher
affinity for the HLA receptor, quantitatively displace the antigen, inhibiting the immune response.
Both approaches would benefit from improved HLA-drug binding, but as the HLA receptors are
highly promiscuous, the binding sites are not specific for any natural amino acid. Unnatural amino
acids, either designed or screened through high-throughput assays, may provide a solution. This
review summarizes the nascent field of using non-canonical residues to treat MS, RA and CD,
focusing on the importance of specific molecular interactions, and provides some examples of the
synthesis of these unnatural residues.
Introduction:
The increasing understanding of the critical role of peptides in human biology has led to a
renewed focus on developing peptide therapeutics. Drug discovery and design has long been
centered on small molecule synthesis.1 However, small molecules lack the precise specificity of
peptides2 and very often have off-target effects due to undesired secondary interactions. The
comparatively large size and specificity of peptides offers a promising alternative. However,
despite this potential, peptides have only seen very limited use as therapeutics partially due to
cellular-uptake concerns, partially due to their low biostability, and partially due to their
comparative synthetic complexity and/or expense.3 However, one of the greatest limiting factors

is the co-evolution challenge. Therapeutic peptides are best suited for inhibiting, blocking, or
agonizing targets that have endogenous peptide ligands with which they have co-evolved over
approximately the past four billion years. Many of the natural targets have exceptional affinity,
and so displacing them is a significant challenge. However, the systems have been developed
exclusively using, with a few very notable exceptions, the canonical 20 amino acids. Using
unnatural amino acids can possibly decouple this problem by introducing residues that can take
advantage of latent interactions unavailable to any natural residue. With recent advances in in silico
peptide design, and access to the significant computational resources required for this type of
research;4 synthetic chemistry to develop new methods to access unnatural amino acids in efficient,
rapid, and general ways;5 the understanding of peptide architectures, sequences, and modifications
to improve proteolytic stability; 6 and solid-phase peptide synthesis to allow for faster, cleaner,
and massively parallel syntheses,7 we are potentially already in a renaissance for peptide-based
drugs.
One of the most promising applications of the new peptide science is for developing new
therapeutics for autoimmune disorders, especially the major histocompatibility complex (MHC)
Type II disorders.8 These are all conditions where an individual carries a certain allele of the
receptor that is capable of improperly identifying a self-peptide as foreign. This initiates an
immune response whose symptoms differ based on the target protein or organ. Thus, the peptides
that cause disease are not the natural ligands of the receptor. This makes them very promising
targets for the therapeutic intervention with synthetic peptides that interfere with the immunogenic
interaction. MHC Type II diseases include many of the most common immune diseases: multiple
sclerosis (MS), celiac disease (CD), rheumatoid arthritis (RA) and type 1 diabetes (T1D) among
many others.9 The presence of the allele significantly increases susceptibility to develop the
disease but is not sufficient for disease onset.10 The overall mechanism in these types of disorders
is very similar.
MHC class II molecules, also known as human leukocyte antigen (HLA) receptors, are
present on the surfaces of epithelial cells.11 They are comprised of a heterodimer of two proteins:
the α and β chains. The peptide antigen binding groove emerges from the organization of two α
helices forming walls, supported by an eight strand β-pleated sheet floor which open on both ends
(Figure 1A).12 These receptors present antigenic peptides to CD4+ T cells initiating an immune
response resulting in disease symptoms. The binding groove and antigenic peptide conformation
is highly conserved between MHC type II molecules. The antigenic peptide is bound in an
extended conformation within the groove and is held in position through non-covalent interactions
between the peptide backbone and sidechains and the surface residues on the receptor.12 Generally,
nine amino acids form the core binding region however the peptide may be longer as the binding
pocket is open on both sides. In the bound conformation, several of the amino acid side-chains
face towards the groove into distinct pockets. These residues form additional attractive interactions
stabilizing the peptide-MHC complex and are termed anchor residues, found in positions p1, p4,
p6 and p9 (Figure 1B). However, this pattern can vary based on the disease and associated peptide.
For example, in some cases, it is p7 instead of p6 which is the anchor residue. The nature of the
pockets (size, shape, hydrophobicity, electrostatic and electronics), as well as the preferred amino
acid residue, varies depending on the exact sequence of the HLA receptor. These factors determine
which peptides it is capable of recognizing, and defines which residues on the peptide epitope are
involved in binding to the HLA. Several of the epitope’s other amino acids in this core HLAbinding sequence of nine amino acids point away from the binding groove and participate in T cell
recognition (Figure 1C). The T-cell uses its receptor then binds from the top face and forms a

MHC-peptide-T cell ternary complex. This interaction then initiates the complicated adaptive
immune response. Although incredibly highly polymorphic across the population, individuals have
only between 8 and 12 different MHC receptors. However, there are approximately 108-1012
different circulating T-cell receptors at any one time, and the best estimates indicate that the genetic
code encodes on the order of 1020 possible different T-cell receptors.13 This difference in
polymorphism is key to the interest that these materials have drawn from researchers using
unnatural amino acids: the MHC receptors need to be capable of binding a very wide variety of
different peptides; they are the primary recognition element for identifying pathogens for the
immune system. However, because they must be promiscuous binders, they are not particularly
strong binders of any given antigen; furthermore, as the pockets and potential interaction points
along their surface must be capable of accepting a number of different amino acid guests, they are
not specific for any given amino acid. As peptides are the natural ligand responsible for disease
initiation, treatment with peptide drugs has been a focus of autoimmune research. There are two
potential mechanisms that can be envisaged. The Altered Peptide Ligands (APLs) attempt to
modulate the T-cell receptor face of the peptide in order to change the T-cell response from a proinflammatory mechanism to an anti-inflammatory mechanism.14 HLA-blockers (HLAB) on the
other hand seek to improve binding to the MHC, and thereby competitively displace the antigenic
peptide and consequently prevent T-cell recognition of the complex altogether.15 APLs do not need
to displace all the antigens to function: they need to occupy sufficient MHC receptors that their
anti-inflammatory response balances the pro-inflammatory response elicited from the antigen.
However, no traditional APL has reached the clinic (although there are a number of candidates,
such as glatiramer triacetate16 that may have some APL activity in addition to other mechanisms).
HLABs on the other hand rely on near complete displacement of the natural antigen. By removing
the antigen, you remove the downstream immune response; but, for this to be viable, displacement
must be near complete, and this implies an exceptional preference of the HLAB over the antigen
for the HLA receptor. However, as the receptor is promiscuous by design, this is very difficult to
do with natural amino acids. The current best efforts are on the order of a 55-fold improvement as
observed by Sollid and co-workers in a CD model.17 But that does not mean that an unnatural
amino acid cannot be designed that is specific for the pocket. These residues could, in theory, show
far higher specific affinity, providing the required orders of magnitude increase in affinity that
could lead to a new class of specific treatments for autoimmune diseases. To do this rationally, a
detailed understanding and modelling of the various potential interactions that can be exploited to
improve affinity is required.

Figure 1. Overview of the MHC-peptide interaction. A) Top-down view of a crystal structure of
an MHC-Type II receptor associated with RA18; B) Cartoon representation of myelin basic peptide
87-99, the immunodominant epitope strongly associated with the development of MS bound to
HLA-DR2, an HLA receptor associated with many cases of MS. Key HLA contact residues are
highlighted in green, key TCR-contact residues in red. The pockets on the HLA are indicated and
their representation is broadly proportional to their respective size. C) Image of a T-cell receptor
(top, yellow coil and pink surface) interacting with the HLA (bottom, grey surface)-antigen
(middle yellow surface) complex obtained from an MS related crystal structure.19
Consideration of the nature and strength of each interaction between the amino acids of the
antigen and the receptor, along with both any emergent negative/positive cooperative role in
binding affinity, and any potential entropic concerns, is essential for the successful development
of unnatural amino acids for treatment. High binding affinities are required to outcompete the
natural antigenic peptide, and incorporating residues which contain stabilizing non-covalent
interactions (i.e., H-bonding, π···π, and X−H···π interactions) are essential, but many of the
binding events are emergent phenomena arising from co-operativity effects including a number of

adjacent residues on both receptor and peptide. Consequently, an in-depth knowledge of the
receptor pockets (i.e. their size, shape, and charge distribution) is absolutely necessary for the
rational design of new unnatural amino acids. Many studies have attempted to improve binding
affinity by substituting these anchor residues for other amino acids (single mutations, double
mutations, alanine scans, randomized libraries, etc), but they have primarily focused on natural
amino acids and few have utilized unnatural amino acids.20
Another key aspect in a successful therapy is modulation of T-cell activation. A highaffinity HLAB may simply elicit an increased immune response, and it is essential to prevent this.
This is where the HLABs and APLs differ: the APLs, through the modification of residues
interacting with the T-cell, seek to modulate the immune response and recruit anti-inflammatory
Th2 cells rather than pro-inflammatory Th1. HLABs seek to modify the T-cell face to prevent Tcell interaction at all. To achieve this goal, strategies including the incorporation of blocking
residues, cyclizations, and crosslinking agents have been explored.
Central to all of this work is the use of new unnatural amino acids, and there are isolated
examples employed for the different MHC Type II conditions. The purpose of this current review,
organized by disease state rather than amino acid structure, is to consider the efforts to date using
unnatural amino acids for the treatment of MHC Type II disorders as a whole rather than as isolated
examples. The variety of methods used for creating these residues, and the challenges of
integrating them into peptides, are readily generalizable from any specific disease to all the various
conditions.
Celiac Disease
Celiac disease is characterized by a lifelong sensitivity to gluten proteins found in wheat,
barley and rye known as gliadins, hordeins and secalins respectively. It affects approximately 1%
of the western population and the number of those affected is expected to increase.21 Ingestion of
gluten causes an immune response that damages the intestinal tract resulting in chronic diarrhea,
malabsorption (causing anemia and vitamin/mineral deficiencies), and a host of related
complications. Currently the only treatment option available is a gluten free diet, which can be
difficult to maintain.22

Figure 2. Energy minimized molecular models derived from the crystal structures23 of the pockets
of interest; the surface represents the HLA (HLA-DQ2), while the α-gliadin, LQPFPQPQLPY, is
represented by the green peptide. A) Overall view of the binding groove with the prolines of the
antigen highlighted in yellow. B) Expanded view of the P1 pocket. The mutated Pheα53 residue
is highlighted in black. In other members of this class it is an arginine, and it extends through the
P1 pocket (outlined in pink), blocking it. C) Expanded view of the P4 (pink outline) and P6 (green
outline) pockets. The Lysβ71 residue that separates the two pockets is highlighted in black, while
the two glutamine residues that occupy (in the case of p6, poorly) are highlighted in yellow. D)
Expanded view of the large, empty, p9 pocket (outlined in pink) partially occupied by tyrosine.
The majority (>90%) of patients express allele HLA-DQ2, while a small portion are
carriers for HLA-DQ8 (5%). The epitope recognition preferences of these two receptors have been
thoroughly studied and are well understood and crystal structures of the receptor bound to gliadin
have been isolated. Gluten peptides are rich in proline and glutamine residues. High proline content
also results in increased peptidase resistance allowing them to avoid degradation and reach the
intestinal tract. Gluten peptides are then recognized by tissue transglutaminase (TTG) which is
capable of deamidating gluten peptides resulting in gliadins which have increased affinity to the
HLA receptor (due to their negative charge) and increased T cell response.24 It is however, possible
in certain cases for HLA-DQ2 to recognize natural gluten peptides, though they are more often
recognized in their deamidated form as gliadins.25 TTG has been shown to participate in wound
healing and apoptosis. It is no surprise then that it is upregulated in inflamed intestinal tissues. It
has been proposed that a viral infection or other environmental factors causing inflammation
trigger TTG. This leads to deamidation of the gliadins present in any wheat-rich diet and onset of
CD.26 α-Gliadin, both the 17mer and 33mer, containing the sequence LQPFPQPQLPY, is the
immunodominant peptides (Crystal structure, 1S9V; Figure 2),23, 27 though many other HLA-DQ2binding peptides are also capable of triggering an immune response.28 The 33mer peptide is

particularly immunogenic due to high protease resistance and the presence of six overlapping
binding epitopes. Trying to target the antigen is challenging as there are many potential antigens.
Trying to interfere with the downstream immune response, i.e. using NSAIDs or corticosteroids,
is the acute treatment but is only partially effective and leads to a general depression of the immune
system, increasing susceptibility to infection. New therapeutic approaches are required and APLs
and HLABs have shown promise. Many of these have used unnatural amino acids to improve
affinity or prevent T-cell recognition.
Whenever unnatural amino acids are to be used, it is essential to have an understanding of
the fundamental interactions of the natural antigen. For the purposes of this review, we will provide
a more detailed analysis of the DQ2 receptor to illustrate the point.23 For other diseases, we will
direct the reader towards the initial crystal structure and computational reports. The HLA-DQ2
receptor has a large pocket at p1. Due to a mutation Argα53, normally conserved in other DQ
molecules and forms hydrogen bonds as a key anchor residue, is missing in the p1 pocket. Its
absence makes the pocket far larger, and allows for the incorporation of a proline in the p1
position.27 Proline residues can also be incorporated at p3, p5, p8 and p9. Glutamic acid, the result
of TTG activity, is preferred in positions 4 and 6 as negatively charged residues form favourable
interactions in these positions (Figure 2). A mutation results in the replacement of the blocked
Tyr30β normally found in the DQ p6 pocket with serine, resulting in a pocket capable of hydrogen
bonding. Nearby Lysβ71 results in preference for negative charges and nearby Tyr9β also
participates in hydrogen bonding; this complex is perfect for a negatively charged residue such as
Glu.23 Argβ70, Asnα62 and Asnα11 were found to form important interactions in p4. It was also
noted that the formation of attractive van der Waals interactions are important for interactions
using p1, p4, and p7; while the residue at p9 was less important in the natural antigen as the pocket
is so large that occupying residues do not form strong interactions with the receptor. Prolines at
positions 5 and 8 face away from the HLA, making them suitable for modifications that affect T
cell recognition (Figure 2).29

Figure 3. Unnatural amino acids utilized in the development of APLs and HLABs for CD.
In one study, hydroxyproline or dihydroxyproline (1, 2; Figure 1) residues were introduced
into the α-gliadin peptide to reduce the binding affinity of gluten.29 The aim was to develop a low
affinity peptide which could then be genetically incorporated into wheat. These modifications can
be achieved both enzymatically and chemically. The hydroxyproline peptides were studied
computationally and it was found that substituting the prolines at positions 5 and 8 slightly
improved binding as they formed better interactions with water. Expanding on this work,
Kapoerchan and coworkers used azidoproline to suppress T cell responses.30 (4S)-4-azido-Lproline (3) or (4R)-4-azido-L-proline (4) were introduced at p3 and p5.31 To further improve their
T-cell blocking activity, they could be readily functionalized post-peptide synthesis using copperassisted azide-alkyne cycloaddition (CuAAAC) chemistry. These azides can be functionalized
with various functional groups such as N-methylacrylamide or N-acryl-L-phenylalanine methyl
ester resulting in amino acids 5-8. Most modified peptides had approximately the same binding
affinity to HLA-DQ2 as the unmodified version however, one case resulted in drastically reduced
binding, which was potentially due to the presence of steric clash between the peptide and HLA
receptor. These modified peptides showed reduced T cell stimulation with larger substituents
showing the lowest T cell stimulation. This illustrates that blocking T-cell recognition is a
potentially viable approach in the prevention T-cell stimulation. However, when studied in a

competition assay, the peptides did not have sufficiently high binding affinity to outcompete
gliadin and prevent T cell activation.
To address this issue, the same team undertook another study to create a high affinity
gliadin analog.32 In this study they took the peptide FVAEYEPVL which was predicted to be a
strong HLA binder and tested N-terminal extensions and single amino acid substitutions. Their
results showed the ADA extension increased binding affinity 5-6 fold while the best binder after
amino acid substitution was found to be ADAYDYESEELFAA. They then used unnatural amino
acids at p1. The p1 pocket is large and hydrophobic, and as mentioned above, natural amino acids
are incapable of completely filling this pocket. Eight unnatural amino acids (structure 9-16; Figure
3) were designed, synthesized, and incorporated into the P1 position in place of the tyrosine. Many
of these molecules had been previously prepared, but several of the syntheses are noteworthy.
The fluorescent derived amino acid Nα-Fmoc-Nβ-(6-N,N’-dimethyl-aminonaphtalimidoyl)L-diamino-propionic acid (6-DMNA) (9) was selected as its increased bulk could provide a good
fit and consequently improve binding. This amino acid was synthesized using 3-nitrobenzaldehyde
(17; Scheme 1) as the starting material. Protection of the aldehyde 18 was followed by nucleophilic
substitution with chloromethyl phenyl sulfone to provide 19. Deprotection, and addition of diethyl
maleate allowed for the in situ cyclization and elimination of the phenylsulfone provides the diester
20. Reductive amination of the nitro group to the amine 21, followed by saponification of the ester
functionality to allow for anhydride formation provides electrophile 22. The anhydride was then
treated with the diaminopropanoic acid derivative 23 (derived from serine)33 to provide maleimide
24. Finally, removal of the allyl ester provides the Fmoc-protected amino acid 25, the protected
derivative of 9, which is suitable for solid-phase synthesis.

Scheme 1. Synthetic procedures for the synthesis of fluorescent Fmoc 25, the protected analogue
of amino acid 9.

Lysine is a large residue, and consequently acts as an excellent platform for elaboration for
filling the p1 pocket. To prevent the repulsion of a positively charged side chain amino acid with
the charged His side chain located on the wall of the pocket, a neutral hydroxyl analogue (10 in
Figure 3) was designed (Scheme 2). Oxidation of the primary alcohol of protected L- homoserine
26 provided aldehyde 27. Wittig olefination with hydroxylated reagent 28, resulted in the
formation of aldehyde 29. Subsequent 1,2 reduction and concomitant transesterification generated
ethyl ester 30. Saponification of the ester provided the de-protected Boc-building block 31.
Replacing the Boc group with an Fmoc group for the required SPPS strategy completes the
synthesis of 10a.

Scheme 2. Synthesis of the Fmoc derivative, 10a, of hydroxylated lysine analogue 10.
In general, using bulkier, and/or charged residues takes advantage of the formation of
stabilizing interactions that are unavailable to the natural residues and was found to increase
binding affinity by factors of 4-5. The incorporation of unnatural amino acids is a promising
approach for increasing the binding affinity of peptides. However further increases in binding
affinity require careful design as the gains using this trial-and-error approach are modest.
Another study by Siegel and coworkers modified the α1-gliadin peptide to incorporate
aldehyde bearing amino acid derivatives (32-36; Figure 3) in the p4 and p6 positions.34 These
aldehyde derivatives are capable of reversibly condensing with Lysβ71 located near the p4 and p6
positions to form an imine. They found when the appropriate length aldehyde 33 was employed,
binding affinity to the DQ2 increases and the dissociation half-life increases by a factor of eight
compared to the unmodified peptide. As expected, either mono-aldehyde peptide also had a much
higher degree of T-cell activation due to their more stable occupation of the HLA receptor. The
dialdehyde substituted peptide, however, decreased T-cell stimulation, which was proposed to be
a result of the structural changes induced on the T-cell binding face due to the mutated residues.
Exploiting this behavior, they then modified the peptide to act as a HLAB based on their previously
reported work.35 This involved replacing two solvent-exposed leucine residues with succinylfunctionalized lysine moieties 38. This new peptide, however, was less effective at preventing Tcell activation despite the incorporation of imine-forming residues (ketones and aldehydes 32-38).
It would be interesting to investigate the biological behaviour of the potent DQ2-binding monoaldehyde peptides functionalized with the blocking residues. The longer half-life and increased

binding affinity would potentially assist the peptide to outcompete gliadin and prevent T cell
proliferation.
The aldehydes (33-36) used in this report were synthesized starting from an Fmoc protected
lysine homologue incorporated in a peptide chain using Boc SPPS (39; Scheme 3). The Fmoc
protecting group was cleaved using 20% piperidine to yield free amine 40. This side chain nitrogen
was capped by coupling an Fmoc protected serine residue to the free amine using HBTU to
generate 41. SPPS can then be continued. Following cleavage from the resin support, the Fmoc
protecting group was removed (43) and then the peptide was treated with sodium periodate at pH
7 in a phosphate solution to produce glyoxamide 44.

Scheme 3. Synthesis of glyoxamide-functionalized amino acid 44 from diamino ethanoic acidderived residue 39.34 R and R1 represent peptide chains or hydrogen if the residue is at the end of
the chain.
In two HLAB studies conducted by Xia and coworkers, three different T-cell inhibitory
mechanisms were investigated.35-36 The first incorporated the same bulky blocking groups in the
p5 and p7 positions: lysine residues modified with succinyl moieties (38).35 A dimeric version of
the unmodified peptide was then synthesized by cross-linking lysine residues in p7 using a
hexaethylene glycol linker. The binding of the succinyl peptides was comparable to the unmodified
peptide, but the dimeric peptide had higher affinity. The dimeric peptides form complexes with
two DQ2 molecules simultaneously; but, this is only observed at pH 5.5. Neither the blocking nor
the dimeric peptides elicited a T cell response, and were both even found to be able to
competitively inhibit T-cell proliferation in the presence of antigenic peptides in a dose dependent
manner.
The second study focused on the synthesis of these dimeric and cyclic peptides.36 Dimeric
peptides which were synthesized using thiol-maleimide bonds were unable to prevent T cell
proliferation. Two types of cyclic peptides were then tested, one in which the core peptide is
flanked by a glycine spacer and then linked via disulfide bond or ones in which there is an internal
cyclization using internal lysine residues and polyethylene glycol linkers. These peptides had
similar or slightly better binding than the reference peptide. The disulfide peptides again did not
inhibit T cell activation while two of the PEG based peptides which used a longer gliadin epitope
did effectively inhibit T cell proliferation. The discrepancy is potentially due to the in situ reduction

of the disulfide bond, cleaving the cycle. Although the binding was deemed insufficiently potent
to act as a true HLAB, it is an excellent proof-of-concept. Combining both dimerization and
cyclization along with increasing peptide-MHC affinity through modifications of anchor residues
may provide an effective therapeutic approach for celiac disease and other MHC type II conditions
in the future.
Rheumatoid Arthritis
Rheumatoid arthritis is the chronic inflammation of the joints caused by an autoimmune
response to the synovium (lining of the joints) which eventually leads to cartilage destruction, bone
erosion, and loss of joint function.37 While it is most commonly associated with joint damage, RA
can also cause complications of the skin, eyes, lungs and heart among other organs and structures.
41 of every 100,000 people will be diagnosed with RA. There is no cure and current treatments
focus on reducing inflammation and preventing disease progression and subsequent join damage.
Many of the drugs that are used to slow progression of the disease modulate various components
of immune system activation or inflammation pathway which results in side effects such as an
increased risk of infection.38
The main genetic factors associated with RA are the HLA receptors HLA-DR1 and HLADR4. The disease etiology is unknown although several potential antigens including proteoglycan,
gp39 and type II collagen have been associated with disease onset. Collagen-induced arthritis is
the most widely used model in the study of RA. The CII250-270 sequence is highly immunogenic,
and CII263-272 is currently believed to be the immunodominant peptide and is recognized by both
HLA-DR4 and DR1 molecules.39 Residues p1 263F and p2 264K were found to be key anchor
residues for HLA-DR binding while residues p5 267Q and p9 270K are the key TCR contact
residues (Figure 4).40

Figure 4. Crystal structures39a of the pockets of interest (energetically minimized); the surface
represents the HLA-DR4, while the CII263–272 peptide is represented by the green peptide. A)
Overall view of the receptor with the key anchoring residues highlighted in yellow. B) Expanded
view of the P1 pocket showing the incomplete fit of a flat Phe. C) View of the P4-6 region
highlighting the importance of backbone-receptor hydrogen bonds to orient the system. D)
Highlight of the P9 pocket showing the incomplete filling of the electropositive surface by the
proline residue.
Modifications using natural amino acids have been extensively studied and have shown
promise in inhibiting T cell activation. This has been most successfully used to substitute the TCR
contact residues to generate APLs that modulate the response into an anti-inflammatory mode.41
One early study into the use of APLs focused on editing the epitope of the CII245-270 peptide to
develop a competitive binder.42 This peptide is a major T cell determinant in I-Aq mice. Key
residues required for T-cell stimulation were substituted with others based on the type I collagen
epitope (245-270) which naturally contains hydroxyproline residues. One promising peptide (I260,
A261, and F263 to A260, hydroxyproline261 and N263) reduced T-cell stimulation and decreased
cytokine production, even when tested in a competition assay with the immunogenic CII245-270.
This observation indicates that it is able to competitively bind to the HLA, and that the mutations
likely affect TCR contact mode as expected.
In a study by Falcioni and coworkers, unnatural amino acids (45-73; Figure 5) were
substituted for both MHC anchor residues as well as TCR contact residues based on computational
modeling to generate heptapeptides.43

Figure 5. Unnatural amino acids used in the development of APLs for RA.
The aim was to create HLABs: improve HLA binding, inhibit TCR recognition and
increase peptide stability. Anchor position p1 was found to have a preference for large cyclic
residues (Tyr, Phe, Trp) in the case of DR1 and several DR4 alleles which preferred simpler
aliphatic chains (Ile, Leu, Val). To make a general candidate, cyclohexyl alanine (45; Figure 5)
was incorporated in this position along with the slightly larger residues (46-48). The canonical
residues Met, Ser, and Leu were found to be optimal for p4, p6, and p7 respectively. The research
team also probed the importance of backbone hydrogen bond formation using N-methylated
derivatives of the amino acids. Hydrogen bonds formed by the amide bonds of the residue at

position p2 and p4 were found to be essential for peptide binding, and loss of these H-bonds
resulted in a several hundred-fold decrease in affinity. In contrast, N-methylation at either p3 or
p5 had little to no effect on binding affinity but greatly increased resistance to protease degradation.
None of the unnatural amino acids (49-51) examined at p2 improved the binding affinity compared
to Arg: the backbone hydrogen bond is critical for binding and changes in the backbone structure
are not tolerated. There is a small hydrophobic pocket near p3 which the authors attempted to
exploit using residues 52-59. These compounds increased binding affinity of the peptide. Due to
the importance of the p4 hydrogen bond, this position was sensitive to substitution, and only 45
and 60 were useful; for p7, residue 62 was found to provide a useful increase to binding affinity.
There is significant diversity in this library, and the synthesis of these amino acids can prove
instructional.
Unnatural amino acids are often considered a recent area of exploration, but the field
stretches back to the beginning of modern synthesis. t-Butyl derivative 62 was first prepared in
1914,44 using pinacolone (74; Scheme 4) as the starting material. Under alkaline conditions,
permanganate oxidation yields trimethylpyruvic acid 75. Condensation of the acid with
hydroxylamine generates oxime 76 that was reduced using zinc dust/acetic acid to amino acid 62.
Enantiospecific approaches to the same target, with higher yields, have also been more recently
developed.45
Scheme 4. The first reported synthetic protocol for 62.44

Unfortunately, despite this significant synthetic effort, a peptide comprising mostly natural
amino acids (except for 24 in p1) showed the best binding to all DR4 alleles; however, this peptide
was also highly susceptible to proteolysis. Inhibition studies showed that several of the synthetic
APLs proved to be good antagonists, despite their lower affinity, when tested in conjunction with
immunogenic peptides; but, 50% inhibition required a roughly 20:1 ratio of HLAB to natural
antigen. One interesting result arising from this work is the reminder that binding affinity does not
directly translate into inhibition as other factors, such as cellular uptake and degradation resistance,
contribute greatly to immunological outcomes. Consequently, peptides with lower binding
affinities may prove to be much better overall antagonists should they be more stable.
In a similar study which continued the work, dipeptide mimetics (63, 64, 77-85) and
glycoconjugates were incorporated into the design of a cathepsin (a peptidase) resistant, high
affinity HLA-DR binder.46 The same preferred sequence motif described above was used as the
baseline starting point for this study. An investigation into the importance of the peptide length
revealed that as the peptide was truncated, affinity decreased. However, one tetrapeptide (Ac(Cyclohexylalanine)RMM-NH2, binding p1-p4) maintained a moderate binding affinity. This
peptide was then extended by integrating a variety of non-amino acid compounds, such as sugars
(i.e., Mannosamine) that can form interactions with the pockets of the HLA in place of the deleted
amino acid residues. In the best cases, similar binding affinities to the parent peptide were

obtained. Dipeptide mimetics (63, 77-85) were incorporated in positions 2-3, 4-5, and 6-7 where
peptide-receptor H-bonds form critical interactions; reducing the freedom of movement may
improve binding. However, all of these dipeptide replacements result in lowering the affinity to
the receptor due to unfavourable steric interactions, but all result in significantly improved
peptidase stability and showed higher levels of T-cell inhibition. These studies highlight the
complexity and non-trivial nature of the design of potential APLs.
Within the series, 7,6 bicyclic pyridizine, 9-aminooctahydro-6,10-dioxo-6H- pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid (64 Figure 6) and a 5-amino-1,2,4,5,6,7hexahydroazepino[3,2,1-hi]indol-4- one-2-carboxylic acid (63 Figure 3) were found to be
acceptable substitutes that maintain the required backbone H-bonds interactions at p2 or p4.
Compound 64 was synthesized via N-acylation of the t-butyl ester of piperazic acid (87;
Scheme 5) with a glutamic acid derivative 86 to provide pseudodipeptide 88.47 Hydrogenolysis
followed by an intramolecular N-acylation provides the seven-membered ring. Deprotection of the
maleimide unmasks the amine 90 and a final cleavage of the t-butyl ester provides the building
block 64. The other members of this class were prepared in an analogous manner.

Scheme 5. Synthesis of 7,6 bicyclic pyridizine, 9-aminooctahydro-6,10-dioxo-6H- pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid 64.47
An alternative class of dipeptides, exemplified by benzo-fused azepinone 63 were prepared
through an intramolecular annulation.48 Indoline (92; Scheme 6) is acylated with the acid fluoride
derivative of protected aspartic acid residue 91 to obtain ester 93. Hydrogenolysis leads to the
formation of acid 94, which is selectively reduced and converted to the diethyl acetal 95 over three
steps (thioester synthesis, Fukuyama reduction and conversion of the aldehyde to the acetal) to set
up the key cycloannulation. Reaction of the acetal with polyphosphoric acid (PPA) generates
unsaturated azepinone 96. Hydrogenation and subsequent removal of the phthalimido group leads
to the formation of the required 7,5-fused azepinone 63.

Scheme 6. Synthesis of benzo-fused azepinone 63.48
As an alternative to this approach, and to increase peptidase resistance, Andersson and
coworkers introduced oxazoles (97-99; Figure 6) into the protein backbone, replacing vulnerable
amide bonds in the CII259-273 peptide and formed oxazole-glycoprotein peptides (example glycofunctionalized amino acid 100).49 These peptides had low binding affinity for mouse Aq but did
bind DR4 (there is a difference in the alignment of the pockets). However, the DR4 binding
peptides also elicited strong T cell response. The reasoning behind the low affinities is unclear but
it may be due to the rigidity of the oxazolone moieties. To further increase stability of the
previously synthesized APLs43 to plasma proteins in addition to the cathepsins, Rosloniec and
coworkers incorporated both oxazolones and other unnatural amino acids into previously tested
APLs (101-103, Figure 7).50 Arginine in p2 was replaced with 101 to prevent its recognition by
tryptic peptidases and the Met resdiue was replaced with norleucine to inhibit T-cell recognition.
These peptides maintained their high affinity for DR4 and could inhibit T-cell activation in a dose
dependent manner and were found to be effective treatments in mouse models for RA. Residue
102 was incorporated because of its high hydrophobicity, which should allow for easier crossing
of membranes and improve peptide uptake. The new peptides maintained their high binding
affinity as well as their ability to inhibit T cell responses. The synthetic procedure for making
compound 102 is interesting as it involves a de novo synthesis of an amino acids (Scheme 7).51
Acylaminomalonate (104) is condensed with cinnamaldehyde (103) under basic conditions to form
a phenylproline analogue, 105. Silane-mediated deoxygenation provides the pyrrolidine 106, and
following monosaponification, the unmasked acid is lost through decarboxylation (107).
Deprotection provides amino acid 108, that is then coupled with enantiomerically pure αmethylbenzylamide using EDC, allowing for resolution of the two diastereomers resulting in 109.

Rigorous cleavage of both amide bonds under forcing conditions liberates the pure amino acid 102
that is protected as the Fmoc derivative for SPPS.

Scheme 7. Synthesis of proline derivative 102 from achiral starting materials through a late stage
resolution.51
As mentioned, the peptides incorporating 102 also make use of achiral oxazole-based
amino acids, and residue 99 is a typical example (Scheme 8).49 The synthesis begins with the
deprotonation of Schiff base 110 using sodium hydride; the anion is quenched with
phenylacetaldehyde. The imine is cleaved to provide the transient intermediate 111 that is isolated
following coupling to glycine to generate dipeptide 112. Oxidation with Dess–Martin periodinane
forms ketone 113, and cyclodehydration using triphenylphosphine, iodine, and triethylamine leads
to the formation of functionalized oxazole intermediate 114. The deprotection of the Boc and t-Bu
groups with TFA followed by N-Fmoc protection generate final product 99a, the protected
analogue of 99. The other members of this rotationally restricted and enzymatically-stabilized class
of residues are prepared in an analogous manner.

Scheme 8. Synthesis of Fmoc-protected oxazole derived amino acid 99.49
In stark contrast to the achiral 99 is carbohydrate amino acid 100. Glycoconjugates are
common building blocks for glycoproteins, but using one as a multivalent hydrogen-bond
donor/acceptor is a creative solution, and the connectivity is highly unusual for an O-linked
glycoside. The synthesis (Scheme 9)52 begins with the commercially available natural (2S,5R)(+)-hydroxylysine dihydrochloride salt 115 being protected as the bis-Boc derivative using
aqueous NaHCO3 and (Boc)2O. The acid is then chemoselectively protected with etherealdiazomethane to obtain the (2S,SR)-(+)-ester 116. A Helferich Koenigs-Knorr glycosylation
provides the O-glycoside 117. Alkaline hydrolysis, and final Boc deprotection results in formation
of the unusual glycoconjugate 100.

Scheme 9. The reported synthetic strategy for glycoconjugate 100.52
The above reports all focused on the collagen type II epitope, but other antigens associated
with DR4 are also potential immunodominant sequences that can act as potential starting points
for designing new therapeutics. Boots and coworkers focused on the generation of APLs using the
gp39263-275 epitope as the parent compound.53 The examples of unnatural amino acids used in APLs
for the treatment of Rheumatoid Arthritis reported by Boots and coworkers (118-125) are provided
in Figure 6.

Figure 6. Unnatural amino acids utilized in APLs for the treatment of Rheumatoid Arthritis.
Based on their investigations, they determined that Phe265 (p1) is the dominant HLA
anchoring residue and that Ala268, Ser269, Glu271 and Thr272 (p4, p5, p7 and p8) are the core
TCR contact residues. They then substituted p1 with a series of unnatural amino acids to attempt
to improve affinity (118-125; Figure 6). They chose to modify the HLA contact residues because
modifications of TCR contact residues could result in undesired immune response as was the case
in clinical trials where patients developed allergic reactions to other APL formulations. This is a
challenge for autoimmune peptide therapies: APLs can often induce dangerous allergic or adverse
reactions in some individuals, leading to the termination of several clinical trials.54 Modification
of the anchor residues can also result in a change in the structure or positioning of the protein, and
this too can lead to altered T-cell responses despite the homology to the parent epitope.
The APLs generated by Boots had similar binding affinities for DR4 as the original
peptides demonstrating the flexibility of the pocket to accept alternatives to a simple phenyl ring.

Of the substitutions tested, only two were found to be partial activators of T cells (compounds 121
and 125). Many of the amino acids have relatively simple preparations, but 121 is a challenging
target.55 Optically active glycinamide (126; Scheme 10) is condensed with substituted
benzaldehyde 127 to produce, in the presence of an acid catalyst, a mixture of diastereomers (128).
These could be readily separated through fractional crystallization to isolate the desired optically
active imidazolidinone 129. Boc protection removes the remaining acidic proton to give precursor
130. Deprotonation creates the enol that is then treated with benzhydryl chloride (131) installs the
required functionality in 132. A series of deprotections: Boc and imidazolidinone hydrolysis,
cleavage of the primary amide, and reduction of the remaining methyl benzyl group, provides the
final amino acid 125.55

Scheme 10. Synthesis of diphenyl substituted amino acid 125.55
However, incorporating this diphenyl substituted amino acid 121 reduced IFN-y
production while 125 increased cytokine production. The exact mechanism for decreased cytokine
production is uncertain. While an interesting approach, this strategy did not result in antagonism
or prevention of disease progression.
Finally, although not a synthetic amino acid in the same class as those described above,
citrullination plays a key role in RA pathogenesis. It can occur because of enzymatic
transformation of arginine 133 to citrulline 134 by peptidyl arginine deiminases (PAD) (Scheme
11). It was observed that autoantibodies in the sera of RA patients are capable of recognizing
citrullinated peptides which are present in the synovium.56 Citrullinated peptides however were
not used as a potential therapy but rather as a diagnostic tool. Cyclization of these peptides (which
are recognized by autoantibodies) increased affinity to the antibodies, and thus were used to detect
their presence in the sera of RA patients more efficiently.57 It was also noted that the collagen II
epitopes can undergo other modifications as well, such as glycosylation, which are also recognized
by T cells indicating a more complex mechanism.58 Citrulline introduction may prove a good
starting point for designing the next generation of unnatural amino acids for the treatment of RA.

Scheme 11. Conversion of peptidyl-arginine to citrulline by the PAD enzyme.
Multiple Sclerosis
Multiple sclerosis is an inflammatory disorder of the central nervous system in which
demyelination of axons occurs along with plaque formation.59 This causes a range of neurological
symptoms such as pain, ataxia, motor deficit, visual impairment.60
MS has a very strong genetic association with HLA class II genes DR15 and DQw6, which
increase susceptibility of individuals.61 Myelin basic protein (MBP), proteolipid protein and
myelin oligodendrocyte glycoprotein are all suspected MS autoantigens; however, MBP appears
the most responsible, and is recognized by the majority of MS patient-derived T-cell lines. The
most antigenic sequence appears to be MPB84-103 which contains the immunodominant epitope
MPB83-99.62 Crystallization of the HLA-MBP-TCR ternary complex (Figure 7; PDB: 1YMM)
reveals key structural aspects of the interactions. The TCR sits off-center over the p2 and p3
positions which contain His and Phe residues respectively.63 These form the major contact points
with the TCRα and TCRβ chains. Lys in P5 makes smaller contributions to TCR binding.
Modifications of the p2 and p3 residues greatly impacted binding and modification of p5 affected
binding to a lesser degree.64 Additionally p4 appears important for determining T-cell activation
as the T-cell receptor interacts directly with the peptide backbone making this position relatively
insensitive to substitution if T-cell activation is to be maintained.
Another crystal structure of the HLA obtained by Smith and coworkers, complexed with
MBP83-97, showed that Val87 and Phe90 (p1 and p4) were the major HLA anchor residues, with
Asn92, Ile93 and Thr95 (p6, p7 and p9 respectively) also playing a supporting role (Crystal
structures (1FV1); Figure 7).65 In this structure, the side chains of His88, Phe89 and Lys91 in p2,
p3 and p5 were oriented away from the pocket which is consistent with the understanding that they
act as TCR contact residues.65a These sites can be modified to alter the binding of APLs with either
the HLA or the TCR.66 It was noted however that mutations in the peptide sequence of MBP87-99
in which Lys91 is mutated to either Arg or Ala and Pro96 is mutated to Ala (generating [Arg91,
Ala96] and [Ala91, Ala96] peptides) resulted in antagonistic peptides even though Lys91 has
minimal contributions to binding, and Pro96 is not a TCR contact residue.67 These modifications
can clearly have an impact on the behavior of the adjacent residues. A study by Mantzourani and
coworkers showed that these modifications resulted in a change in peptide conformation: the
essential TCR anchors at p2 and p3 becoming buried into the peptide groove.68 This acts as an
additional reminder about the complexity of these systems, and emphasizes again the necessity to
consider the emergent conformational changes that arise from any substitution.

Figure 7. Crystal structures (1FV1)69 and the electrostatic surface map of the HLA-DR15 binding
pocket with the antigen MBP83-97 highlighted in green. A) Overall view of the peptide-HLA
interaction. B) View of the T-cell receptor-antigen-HLA ternary complex. The key TCRinteracting residues, His88, Phe89 and Lys91 are highlighted in yellow. The surface of the TCR is
provided as a translucent grey model, and the HLA is represented by the ribbons. The surface has
been removed for clarity. C) Expanded view of the very large p4 pocket partially occupied by a
phenylalanine. D) Edge-on view of the peptide showing the interaction between the threonine and
the P9 pocket and end of the binding groove. MBP bends away from the groove and into the solvent
at this C-terminus.
In a study conducted by Trager and coworkers, APL peptides were modified with azapeptide linkages in which a carbon in the backbone is replaced by a nitrogen in an attempt to
increase protease resistance.70 The APL they chose to modify had undergone clinical trials and
patients developed an allergic reaction to the peptide.71 It was hypothesized that this was caused
by use of large doses which were required due to the low bioavailability and stability of the
peptide.71 This peptide sequence contains TCR contacts in p3 (Gln) and p6 (Pro) and HLA contacts
in p4 (Ser) p6(Lys) and p9 (Ser), with aza-glycine being introduced at or near TCR contact points.
Incorporation of aza-gly in p3, along with p4 substitutions to Tyr to increase HLA binding, resulted
in the most effective APL: it demonstrated a longer half-life and acted as a partial agonist. In vivo
studies in EAE mice showed this peptide was effective in treatment of the disease.
Cyclization of peptides offers a potential solution to the instability of linear peptides and
is of great interest.72 Peptide cyclizations of previously tested antagonizers based on the MBP83-99
immunodominant epitope were synthesized and tested. In one case, the mutant peptide
[Ala91]MBP83-99 and several analogues were cyclized in a head to tail fashion.73. Ala91 was
replaced with several other amino acids, and in some cases double mutants were generated to
include mutation of Pro96 to Ala96. In the unmodified peptide, Val87 and Phe90 act as MHC
anchor residues while His88, Phe89 and Lys91 are TCR contacts.74 The cyclic analogues were

found to be good inhibitors of EAE in mice and inhibit IFN-y production. Additionally,
conjugation with reduced mannan through a linker peptide which resulted in increased Th2
response via production of IL-4.75 Mannan incorporation can induce either Th1 or Th2 responses
depending on whether it is oxidized or reduced via binding to receptors on antigen presenting cells.
In a similar study, various cyclic analogues were tested for immunogenicity using blood
mononuclear cells obtained from MS patients.76 These analogues were also based on the MPB8799 epitope and contained mutations at positions 91 and 96 (Lys91 to Arg and Pro96 to Ala double
mutant; or only Pro96 to Ala96, single mutant). Both peptides promoted a Th2 cytokine profile and
inhibited T cell proliferation. Both were also capable of preventing the development of EAE in
mice when co-injected with an immunogenic peptide. The cyclic peptides also showed increased
stability to proteases compared to non-cyclized peptides. The double mutant cyclo[Ala91, Ala96]
MBP87-99 was also conjugated to reduced mannan and further reduced the Th1 profile.75 Another
cyclic peptide of [Phe91]MBP83-99 conjugated to mannan also prevented T cell proliferation.77
In another study, the cyclic and linear [Ala96]MBP87-99 was citrullinated, replacing Arg91
and Arg97 post-synthetically using isolated PAD enzyme (see Scheme 11 above).78 Citrullination
has been implicated in other MHC type II autoimmune disorders such as RA as described above:
citrullinated peptides appear to be generally highly antigenic.79 As such peptide modifications are
common, and even more so in MS patients where the majority of MPB is citrullinated,
understanding the mechanism and effects on disease progression is desirable. The citrullinated
peptides induced a Th1 response confirming that this modification is indeed immunogenic, and
modification of antagonist peptides leads to inflammatory response. In both peptides, citrullinated
residues point towards the TCR indicating that their recognition may be responsible for T cell
activation rather than for improving binding to the HLA. The cyclic and linear citrullinated
peptides were also conjugated to reduced mannan using a KLH carrier.80 The cyclic-KLH-mannan
complex induced a very strong T-cell proliferation response and enhanced cytokine IFN-γ and IL4 production. The linear peptide, on the other hand, did not stimulate either T-cell proliferation or
IFN-γ production. Molecular dynamics simulations of the cyclic peptide revealed that it prefers to
sit in the middle of the binding pocket with F90 and N92 of the cyclic peptide occupying anchor
positions p4 and p6, while p1 and p9 remain empty presumably due to strain induced by the
macrocycle. In contrast, the citrullinated-linear-mannan peptide showed a similar conformation to
the unmodified peptide. Differences in their T-cell activation profile can thus be attributed to the
structural differences of the two peptides. Several studies have also focused on the use APLs based
on myelin oligodendrocyte glycoprotein, another antigenic peptide implicated in MS disease
progression.81 In one study, the immunogenic MOG35-55 peptide was cyclized in a head to tail
fashion.82 This peptide was shown to reduce symptoms and severity of EAE. Computational
modeling illustrated that this peptide binds HLA-DR2 with decreased affinity. Cyclization then
results in different TCR contact points which the authors believe may result in TCR antagonism.
Another study utilized MOG35-55 mutants in which TCR contact residues Arg41 and Arg46 were
mutated with Ala to generate single or double mutants.83 These were compared to cyclic analogues
generated by mutating those Arg residues to Lysine and cyclized to Lys55 (terminal lysine)
through a side chain. While both were found to suppress EAE, the linear peptides had a stronger
effect and cyclic peptides less so.
Another method utilized of increased stability is incorporation of β-amino acids, which
was applied to prepare altered peptide ligands based on the MOG35-55 peptide.84 In this study,
residue 44F, a TCR contact residue, was replaced with either β-A or β-F. The resulting peptides
had increased half-lives, potentially due to the removal of a peptidase recognition site within the

core region of the peptide. Not, only that, but the peptide was found to suppress EAE, even when
administered orally. This small change had a profound impact on the function of the immunogenic
peptide. Adding the additional atom in the peptide backbone slightly shifts the entire register of
the system, and so again has significant distal effects on the interaction between receptor and
peptide. β amino acids substitutions85 may prove to offer a simple solution of introducing unusual
spacing and functionality as they can both increase protease resistance and potentially introduce
the desired antagonistic properties.
The effects of Thiopalmitoylation on peptide ligands in MS have also been examined.86
Thiopalmitoylation is the attachment of palmitic acid to cysteine residues via a thioester bond.87
Myelin proteolipid protein (PLP) is abundant in the central nervous system, is often acylated, and
has been found to be immunogenic in some MS patients.88 Thiopalmitoylation of PLP104-117 and
PLP139-151, the immunogenic epitopes, was shown to increase immunogenicity of the peptides.89
The linkage was also found to be important as amide linkage at the N terminus of the peptides to
palmitic acid did not result in immunogenic peptides.89 A follow-up study to determine the
mechanism for increased immunogenicity determined that lipopeptides are absorbed more
efficiently in antigen presenting cells.90 Cloake and coworkers then modified PLP APLs which
were shown to ameliorate EAE disease progression by promoting the uptake and preferential
presentation of the modified peptides.91 These studies show that the consideration of post
translational modifications of the peptides is important. Finally, in addition to modifying contact
residues, modifications which affect uptake and promotion should also be considered.
MS is potentially the most promising target of APL and HLAB intervention, and
consequently it is a surprise that so little research has been conducted into the use of unnatural
amino acids in this disease compared with RA and CD. The solutions from those two diseases
should transfer well to this system.
Final thoughts
One final example, while not strictly for an autoimmune disease, deserves mention in this
work. All of the examples described above involve some form of design, whether it be chemical
intuition, or some level of computer-assisted design. However, in example after example, the
unintended emergent effects induced on surrounding residues has often had a larger impact on
binding efficiency or T-cell blocking or modulation than the changed residue. Without a doubt,
designed peptides will provide the greatest potential for success in delivering clinically useful
APLs or HLABs, but the design problems are significant. The peptides are large, and the receptors
are enormous. Solvation and entropic factors must be considered, and these are computationally
very intensive and so limit throughput. In a very interesting study Ovaa, Rodenko and co-workers
investigated the binding affinity of a consensus antigen for HLA-A2,92 a receptor that could be
exploited for the development of new anti-viral vaccine formulations. Instead of the careful
deliberation, a massively parallel library of epitopes incorporating unnatural amino acids at
random positions, of which those provided as Figure 8 are simply a few examples, was prepared.
Surprisingly, a large number of the generated epitopes showed considerably higher affinity for the
receptor than the consensus sequence. In some cases, this improvement in affinity was by two
orders of magnitude. These are generally far simpler residues than those described above. Small
alkylated systems (60,62,135-140), or residues with the incorporation of simple π-systems
(120,122,141-145), or slight modification of the natural residues (1, 146-149). If randomly
substituting these residues into a peptide can lead to a two-order of magnitude improvement in

binding affinity, rational design of unnatural amino acids could very well lead to the many orders
of magnitude improvement in binding required for the development of clinically-relevant HLABs.

Figure 8. Most effective unnatural amino acids used by Hoppes and co-workers in their
investigation into random substitution of residues into HLA-binding epitopes.
Conclusion
HLA-specific therapy promises specific targeted treatment options for these and other
autoimmune disorders using APLs and HLABs. These ligands bind to the HLA receptor and
through either differential T cell recognition/activation or blocking are able to reduce or even in
some cases inhibit these diseases; however, there are three major requirements for these drugs:
efficient HLA binding, T-cell blocking or response modulation and protease resistance.
Unfortunately, restricting options to the canonical 20 amino acids has failed to properly balance
these three requirements. Although the incorporation of unnatural amino acids and using other
peptide modification strategies, including cyclization and dimerization has provided encouraging
preliminary results in providing high binding affinity, high protease resistance, and efficient T-cell
blocking or modulation, the resulting peptides still lack ideal behavior. The rapid increase in
computing power and the increasing understanding of receptor-ligand interactions will allow for
improvements in designing predictive in silico techniques to help with residue design.
Consequently, the next generation of therapeutic candidates will involve the combination of
innovative synthetic chemistry, advanced computational modelling, and creative peptide
architecture. Autoimmune HLABs and APLs provide an excellent platform for carrying out
fundamental research into peptide science while offering an ideal application for exploiting
unnatural amino acids for a biomedical application.
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